Loading...
XNAS
PEPG
Market cap49mUSD
Jun 10, Last price  
1.50USD
1D
-1.32%
1Q
-39.27%
IPO
-87.39%
Name

PepGen Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
7.12%
Rev. gr., 5y
%
Revenues
0k
Net income
-90m
L+14.44%
-1,346,000-1,881,000-27,281,000-69,104,000-78,626,000-89,981,000
CFO
-82m
L+19.38%
-885,000-1,652,000-22,599,000-59,265,000-68,997,000-82,372,000

Profile

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
IPO date
May 06, 2022
Employees
54
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
97,739
85,950
68,794
Unusual Expense (Income)
NOPBT
(97,739)
(85,950)
(68,794)
NOPBT Margin
Operating Taxes
617
73
3,706
Tax Rate
NOPAT
(98,356)
(86,023)
(72,500)
Net income
(89,981)
14.44%
(78,626)
13.78%
(69,104)
153.30%
Dividends
Dividend yield
Proceeds from repurchase of equity
86,778
(189)
112,193
BB yield
-72.50%
0.12%
-35.39%
Debt
Debt current
3,094
6,008
5,553
Long-term debt
34,228
37,204
43,515
Deferred revenue
Other long-term liabilities
Net debt
(82,869)
(67,195)
(134,157)
Cash flow
Cash from operating activities
(82,372)
(68,997)
(59,265)
CAPEX
(497)
(2,599)
(3,755)
Cash from investing activities
(37,668)
(32,003)
(3,755)
Cash from financing activities
88,749
(189)
112
FCF
(95,120)
(84,523)
(101,748)
Balance
Cash
120,191
110,407
181,752
Long term investments
1,473
Excess cash
120,191
110,407
183,225
Stockholders' equity
(271,437)
(181,446)
114,505
Invested Capital
408,718
312,975
86,412
ROIC
ROCE
EV
Common stock shares outstanding
31,583
23,796
23,713
Price
3.79
-44.26%
6.80
-49.14%
13.37
 
Market cap
119,700
-26.03%
161,813
-48.96%
317,045
 
EV
36,831
94,618
400,328
EBITDA
(92,486)
(84,766)
(68,301)
EV/EBITDA
Interest
3,396
Interest/NOPBT